Published in Int J Neuropsychopharmacol on April 28, 2005
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol (2011) 1.31
Personalized medicine in psychiatry: problems and promises. BMC Med (2013) 1.09
Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull (2008) 1.02
Pharmacogenetics of antipsychotics. Can J Psychiatry (2014) 1.02
The promise and reality of pharmacogenetics in psychiatry. Psychiatr Clin North Am (2010) 0.92
Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci (2009) 0.92
Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome (2011) 0.89
Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex. Biol Psychiatry (2012) 0.86
A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet (2010) 0.84
Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol (2008) 0.83
Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations. Drugs Context (2014) 0.82
Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol (2007) 0.82
Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms. Br J Clin Pharmacol (2014) 0.82
Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology (Berl) (2006) 0.81
Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. Dialogues Clin Neurosci (2006) 0.80
Family-based clinical associations and functional characterization of the serotonin 2A receptor gene (HTR2A) in autism spectrum disorder. Autism Res (2014) 0.78
Antipsychotic-induced movement disorders in long-stay psychiatric patients and 45 tag SNPs in 7 candidate genes: a prospective study. PLoS One (2012) 0.78
Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians. Neuropsychiatr Dis Treat (2007) 0.77
Pharmacogenetics and outcome with antipsychotic drugs. Dialogues Clin Neurosci (2014) 0.76
Genetics of adverse reactions to haloperidol in a mouse diallel: a drug-placebo experiment and Bayesian causal analysis. Genetics (2013) 0.76
Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders. Pharmgenomics Pers Med (2014) 0.75
Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci (2016) 0.75
T102C polymorphism of serotonin-2A receptor gene in Turkish schizophrenia patients: Association with cognitive impairment and soft neurological signs. Indian J Psychiatry (2014) 0.75
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet (2006) 6.27
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci U S A (2009) 3.49
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 3.35
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A (2002) 3.11
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med (2010) 2.86
Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One (2009) 2.85
Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophr Bull (2003) 2.76
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry (2004) 2.54
A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr Bull (2008) 2.35
Enabling collaborative research using the Biomedical Informatics Research Network (BIRN). J Am Med Inform Assoc (2011) 2.24
Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry (2006) 2.23
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol (2005) 2.10
ZNF804A and schizophrenia susceptibility in Asian populations. Am J Med Genet B Neuropsychiatr Genet (2012) 2.06
Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol (2002) 2.03
Evidence that 'food addiction' is a valid phenotype of obesity. Appetite (2011) 2.02
The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. Am J Hum Genet (2002) 1.98
Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics (2013) 1.97
A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum Mol Genet (2009) 1.93
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Targeted next-generation sequencing appoints c16orf57 as clericuzio-type poikiloderma with neutropenia gene. Am J Hum Genet (2009) 1.85
Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res (2010) 1.79
Age-related decline in white matter tract integrity and cognitive performance: a DTI tractography and structural equation modeling study. Neurobiol Aging (2010) 1.77
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Dopamine for "wanting" and opioids for "liking": a comparison of obese adults with and without binge eating. Obesity (Silver Spring) (2009) 1.65
Association between serotonin transporter gene and borderline personality disorder. J Psychiatr Res (2006) 1.64
Movements in brain death: a systematic review. Can J Neurol Sci (2009) 1.63
Pharmacogenetics of psychotropic drug response. Am J Psychiatry (2004) 1.61
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry (2007) 1.60
Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations. Cogn Neuropsychiatry (2009) 1.60
Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord (2003) 1.59
Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs (2005) 1.55
ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology (2006) 1.49
Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. Am J Hum Genet (2012) 1.47
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) (2008) 1.46
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev (2008) 1.46
Diffusion tensor tractography findings in schizophrenia across the adult lifespan. Brain (2010) 1.43
Connexin 50 gene on human chromosome 1q21 is associated with schizophrenia in matched case control and family-based studies. J Med Genet (2007) 1.42
Pharmacogenetics in psychiatry satellite meeting at the American College of Neuropsychopharmacology, 2000. Neuropsychopharmacology (2002) 1.39
Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) (2004) 1.39
Identifying gene regulatory networks in schizophrenia. Neuroimage (2010) 1.34
Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull (2012) 1.33
SNP-based pathway enrichment analysis for genome-wide association studies. BMC Bioinformatics (2011) 1.31
A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry (2005) 1.31
Reward sensitivity and the D2 dopamine receptor gene: A case-control study of binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.31
Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci (2007) 1.30
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) (2009) 1.28
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry (2010) 1.27
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
Early age at onset as a risk factor for poor outcome of bipolar disorder. J Psychiatr Res (2003) 1.27
Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry (2007) 1.25
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull (2003) 1.24
Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav (2014) 1.23
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology (2002) 1.23
SNPLims: a data management system for genome wide association studies. BMC Bioinformatics (2008) 1.23
Genome scan for susceptibility loci for schizophrenia and bipolar disorder. Biol Psychiatry (2002) 1.23
Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. Int J Neuropsychopharmacol (2008) 1.22
Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex. J Psychiatr Res (2013) 1.20
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
AHI1, a pivotal neurodevelopmental gene, and C6orf217 are associated with susceptibility to schizophrenia. Eur J Hum Genet (2006) 1.19
Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet (2009) 1.18
Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry (2009) 1.18
N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr Res (2006) 1.18
Decision-making deficits and overeating: a risk model for obesity. Obes Res (2004) 1.16
Functional and structural brain correlates of theory of mind and empathy deficits in schizophrenia. Schizophr Res (2009) 1.14
Anxiety as a predictor of relapse in detoxified alcohol-dependent patients. Alcohol Alcohol (2002) 1.14
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol (2004) 1.13
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. Am J Psychiatry (2004) 1.12
Linkage of M5 muscarinic and alpha7-nicotinic receptor genes on 15q13 to schizophrenia. Neuropsychobiology (2004) 1.10
Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology (2006) 1.09
Common genetic variants and haplotypes in renal CLCNKA gene are associated to salt-sensitive hypertension. Hum Mol Genet (2007) 1.09